Arca
Skip to content
Tools
Tools

NDA 212122: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 212122's history or AstraZeneca Pharmaceuticals's company page.

On Sep 30, 2019, FDA declined to approve NDA 212122 (NDA 212122) from AstraZeneca AB in its present form, citing clinical. The application was later approved.

  • Letter date: Sep 30, 2019
  • Application: NDA 212122
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Clinical

The Letter

Text from openFDA; FDA's scanned original (PDF) โ†—

Dear Dr. Small:

Please refer to your new drug application (NDA) dated and received on November 30, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Breztri Aerosphere (budesonide, glycopyrrolate and formoterol fumarate) 160/9/4.8 mcg Inhalation Aerosol.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

CLINICAL

The submitted data do not provide substantial evidence of the efficacy and safety for the use of Breztri Aerosphere (budesonide, glycopyrrolate and formoterol fumarate) 160/9/4.8 mcg Inhalation Aerosol for the proposed indication of the aa, maintenance treatment of ยป patients with chronic obstructive pulmonary disease (COPD) ยฉยฎ The single Breztri Aerosphere phase 3 pivotal trial failed on the co-primary endpoint of change from baseline in trough FEV, for the comparison of Breztri Aerosphere and the glycopyrrolate and formoterol fumarate combination. Therefore, the submitted data do not establish the contribution of budesonide to the Breztri Aerosphere combination product. Furthermore, due to failure at the co-primary endpoint, all secondary endpoints in the single phase 3 pivotal trial failed to show statistical significance and did not provide supportive evidence of efficacy. Moreover, as only a single Breztri Aerosphere phase 3 pivotal trial was submitted with this application, there was no additional data to directly support the efficacy and safety of Breztri Aerosphere.

Information to Resolve Deficiency

In order to address the above deficiency, conduct an additional trial or trials to provide data to demonstrate the efficacy of the Breztri Aerosphere combination product and the contribution of budesonide to the combination product.

PRESCRIBING INFORMATION

(1) We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the PLR Requirements for Prescribing Informationโ€™ and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) - a checklist of important format items from labeling regulations and guidances.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 314.50(I)(1)(i)] in structured product labeling (SPL) format as described at FDA.gov.?

PROPRIETARY NAME

(2) Please refer to correspondence dated, March 8, 2019, which addresses the proposed proprietary name, Breztri Aerosphere. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to the application deficiencies.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

(1) Describe in detail any significant changes or findings in the safety profile.

" http:/;jwww.fda.gov/Drugs/GuidanceComplianceRegulatory|nformation/LawsActsandRules/ucm08415 9.htm

2 http://www. fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm09330 7.htm

3 http://www.fda.gov/Forlndustry/DataStandards/StructuredProductLabeling/default.htm

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:

e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.

e Present tabulations of the new safety data combined with the original application data.

e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above.

e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials.

(3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.

(4) Provide case report forms and narrative summaries for each patient who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.

(5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.

(6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

(7) Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

(8) Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under

21 CFR 314. You may also request an extension of time in which to resubmit the application.

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Linda Ebonine, Regulatory Project Manager, at 240-402- 4483.

Sincerely, {See appended electronic signature page}

Sally Seymour, MD

Division Director

Division of Pulmonary, Allergy, and Rheumatology Products Office of Drug Evaluation II

Center for Drug Evaluation and Research

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Signature Page 1 of 1

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

SALLY M SEYMOUR

09/30/2019 11:45:41 AM

AstraZeneca Pharmaceuticals's Other Letters

Newest first
  • AnifrolumabOct 10, 2025 ยท BLA 761451 ยท not approved

Record

Company
AstraZeneca AB
Application
NDA 212122
Status in openFDA
Approved
Review division
Office of Drug Evaluation II

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.